Z
Zeltiq Aesthetics
As a medical device company, we’re subject to strict regulation on social: https://t.co/BXmaGksFdX. Product & Safety Info: https://t.co/havhXbW9TF
About Zeltiq Aesthetics
Zeltiq Aesthetics, established in 2005 as Juniper Medical, Inc., developed a significant presence in the medical technology sector by commercializing products based on its proprietary controlled-cooling technology platform. The company was founded by Mitchell Levinson, who had prior experience leading Thermage, a firm specializing in radio frequency skin tightening. The foundational science for Zeltiq's core product was developed by Harvard scientists Dr. Dieter Manstein and Dr. R. Rox Anderson at Massachusetts General Hospital, who observed that fat cells were more sensitive to cold than surrounding tissues—an insight sparked by noticing children who frequently ate popsicles developed cheek dimples. Zeltiq exclusively licensed the patent filings for this process, known as cryolipolysis.
The company's flagship product is the CoolSculpting system, designed to selectively reduce stubborn fat bulges non-invasively. This procedure works by applying controlled cooling to a targeted area, which freezes and eliminates fat cells through a natural biological process called apoptosis, without harming the skin or surrounding tissues. The body's immune response then gradually eliminates these dead cells over several weeks, resulting in a reduction of the fat layer. The FDA first cleared the CoolSculpting system in 2010 for reducing fat around the flanks (love handles) and subsequently approved it for other areas like the abdomen, thighs, and under the chin.
Zeltiq's business model focused on a dual revenue stream: the initial sale of the CoolSculpting system to practitioners and ongoing revenue from the sale of consumables, or procedure packs, required for each treatment. The company primarily targets dermatologists, plastic surgeons, and other aesthetic specialists, providing them with a high-demand, cash-pay procedure that complements their existing offerings. This model proved successful, with the company going public in 2011 after raising approximately $75 million in venture funding. By 2016, Zeltiq reported sales of over $350 million. A significant milestone occurred in February 2017 when Allergan announced its acquisition of Zeltiq for approximately $2.48 billion, a deal completed in April 2017. This move integrated CoolSculpting into Allergan's broader aesthetics portfolio, creating a comprehensive offering for aesthetic practitioners.
Source: Dealroom company dataNews
Open roles
Zeltiq Aesthetics in the Pleasanton ecosystem
The Zeltiq Aesthetics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later2 investors entered at this stage
Venrock
Aisling Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Zeltiq Aesthetics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Zeltiq Aesthetics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.


